Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atezolizumab in pediatric and young adult patients with previously treated solid tumors and lymphomas
NL-OMON47877Phase 2Active, not recruiting
- Sponsor
- Roche
- Start
- Jan 2016
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of atezolizumab in Nonhematologic neoplasms, lymphoma, neuroblastoma and 9 more, sponsored by Roche. Primary endpoints: Objective response, Clinical benefit response and 1 more. Started Jan 2016; status: active, not recruiting.
02
Drugs
atezolizumab
03
Conditions
Nonhematologic neoplasmslymphomaneuroblastomarhabdomyosarcoma (RMS)soft tissue sarcoma (STS)
Beyond the preview
Go deeper on NL-OMON47877.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON47877.